Group 1: Company Performance - Sunny Optical (02382) reported an annual revenue of approximately 43.23 billion RMB, a year-on-year increase of 12.9%, and a net profit attributable to shareholders that grew by 71.9%, with a final dividend of 1.206 HKD per share, totaling around 1.301 billion HKD, achieving a dividend yield of about 25%, a recent high [1] - TCL Electronics (01070) saw a rise of over 12% after announcing a framework agreement with Sony to establish a joint venture, acquiring 51% of the new company and fully purchasing Sony's subsidiary in Malaysia for 75.399 billion JPY (approximately 3.781 billion HKD) [1] - Cambridge Technology (06166) reported a revenue of approximately 4.8234 billion RMB for 2025, a year-on-year increase of 32.07%, and a net profit of about 263 million RMB, up 58.08%, with a proposed cash dividend of 0.28 RMB per share [3] - HaiXi New Drug (02637) reported a revenue of approximately 582 million RMB for 2025, a year-on-year increase of 24.79%, and a net profit of about 177 million RMB, up 30.09%, with earnings per share of 2.55 RMB [4] Group 2: Market Trends - Aluminum stocks continued to rise, with China Aluminum (02600) up 4.09%, Nanshan Aluminum International (02610) up 3.83%, and China Hongqiao (01378) up 3.22%, following substantial production cuts from two Middle Eastern aluminum companies, which announced a 20% reduction in output by 2026 [2] - Semiconductor stocks rebounded, with companies like Lanqi Technology (06809) rising by 8.12% and Zhaoyi Innovation (03986) by 5.31%, driven by a strong performance in the South Korean market where Samsung Electronics and SK Hynix saw significant gains [2] - The aviation sector experienced a collective rebound, with China National Aviation (00753) up 6.13% and China Eastern Airlines (00670) up 6.88%, influenced by geopolitical developments in Iran [4] Group 3: Strategic Partnerships - Elysium AI (03696) surged over 10% following a significant partnership with Eli Lilly, granting Eli Lilly exclusive sales rights to a GLP-1 diabetes drug developed using Elysium's AI technology, with an upfront payment of 115 million USD and a total potential value of up to 2.75 billion USD [3]

Financial Performance - For the year ending December 31, 2025, the total revenue was RMB 582,358,000, an increase of 24.79% compared to RMB 466,683,000 in 2024[3] - The net profit for the year ending December 31, 2025, was RMB 177,029,000, reflecting a growth of 30.09% from RMB 136,079,000 in 2024[3] - Earnings per share for the year ending December 31, 2025, were RMB 2.55, up 26.24% from RMB 2.02 in 2024[3] - The total pre-tax profit for 2025 was RMB 198,076 thousand, up from RMB 148,994 thousand in 2024, reflecting an increase of about 32.9%[18] - The company reported a significant increase in sales of pharmaceutical products, with revenue rising to RMB 581,055 thousand in 2025 from RMB 461,529 thousand in 2024, marking a growth of approximately 25.8%[15] - The company's annual profit for 2025 was RMB 177,029,000, up 30.1% from RMB 136,079,000 in 2024[27] - Gross profit for the year ended December 31, 2025, was RMB 485,557,000, up 25.40% from RMB 387,194,000 for the year ended December 31, 2024, with a gross margin of 83.38%[49] Research and Development - Research and development expenses for the year were RMB 73,504,000, compared to RMB 67,525,000 in 2024, indicating an increase in investment in innovation[4] - The innovative drug division's R&D expenses for 2025 were RMB 48,954 thousand, compared to RMB 47,804 thousand in 2024, showing a slight increase of about 2.4%[20] - The company has two product development platforms, including a multi-target innovative drug development platform and a generic drug development platform, which support its research and development capabilities[40] - The company is focused on advancing innovative drug research projects and expects significant progress in clinical trials and additional IND submissions[46] - The company has made significant progress in its R&D efforts, with a focus on identifying high-potential therapeutic targets for commercialization[40] Financial Position - The total assets less current liabilities amounted to RMB 1,618,418,000 as of December 31, 2025, compared to RMB 573,746,000 in 2024[5] - Cash and cash equivalents increased significantly to RMB 645,054,000 from RMB 38,282,000 in 2024, indicating improved liquidity[5] - The company’s total equity reached RMB 1,593,733,000, a substantial increase from RMB 541,327,000 in 2024, reflecting strong financial health[6] - The company’s current assets as of December 31, 2025, were RMB 1,212,210,000, with a current ratio of 6.31, significantly up from RMB 164,185,000 and a current ratio of 1.9 as of December 31, 2024[58] - Total liabilities decreased to RMB 131,919,000 in 2025 from RMB 144,317,000 in 2024, indicating a reduction of 8.5%[30] Market and Product Development - The company is engaged in the research, development, production, and sales of pharmaceutical products, indicating a focus on the healthcare sector[8] - As of December 31, 2025, the company has commercialized a product portfolio primarily consisting of 15 approved generic drugs, contributing to its status as a major player in China's pharmaceutical industry[33] - The company has a diverse pipeline of innovative drugs, including one oral drug for wAMD/DME/RVO, which is currently in clinical development[42] - The innovative drug C019199, targeting multiple cancer types, has completed Phase I clinical trials for osteosarcoma and TGCT, with Phase III trials expected to start in China in the first half of 2026[43] - HXP056, an innovative drug aimed at treating retinal diseases, is anticipated to be the first oral treatment for wAMD/DME/RVO, with promising initial safety and efficacy data from Phase I trials[44] Corporate Governance and Compliance - The company has adopted the corporate governance code as per the listing rules and has complied with all applicable provisions since its listing date on October 20, 2025[78] - The audit committee has approved the annual performance and consolidated financial statements for the reporting period, which will be submitted to the board for approval[82] - The remuneration and assessment committee is responsible for evaluating the performance standards of directors and senior management, as well as overseeing the implementation of compensation plans[83] - The strategic committee is tasked with researching the company's long-term development strategy and major investments, ensuring effective implementation of these strategies[85] - The company has confirmed compliance with the standard code for securities trading by all directors and supervisors since its listing date[79] Capital and Financing - The net proceeds from the global offering completed on October 20, 2025, amounted to approximately HKD 940.13 million[73] - The planned allocation of the net proceeds includes 52.0% for ongoing R&D investments, 23.0% for enhancing R&D capabilities, and 8.0% for expanding market influence[74] - The company's financing costs decreased to RMB 5,736,000 for the year ended December 31, 2025, down from RMB 7,221,000 for the year ended December 31, 2024, mainly due to a reduction in the book value of other borrowings[53] - The debt-to-equity ratio increased from 3.29% as of December 31, 2024, to 4.93% as of December 31, 2025, primarily due to the increase in share capital and retained earnings[64] - Approximately 75.68% of total borrowings were at fixed interest rates, while 24.32% were at floating rates, with the board considering the interest rate risk from floating rate borrowings to be minimal[62] Legal and Regulatory Matters - The company has not entered into any hedging transactions for foreign exchange or interest rate risks as of December 31, 2025[65] - There were no significant legal proceedings or contingent liabilities as of December 31, 2025[70] - The company did not declare any dividends for the years ending December 31, 2025, and 2024[26] - The board does not recommend the distribution of a final dividend for the year ended December 31, 2025[75] - The company has not purchased, sold, or redeemed any listed securities from its listing date until December 31, 2025, and holds no treasury shares as of December 31, 2025[81]

福建海西新藥創制股份有限公司（「本公司」）董事會（「董事會」）宣佈，本公司創新 藥物項目HXP056，即有望成為全球首款針對出血性視網膜疾病的口服藥物，已於 2025年7月初啟動中國濕性年齡相關性黃斑變性(wAMD)患者招募，目前已完成一 期臨床試驗中單次給藥劑量遞增(SAD)與多次給藥劑量遞增(MAD)階段的所有患者 招募工作，並在連續給藥四週後完成劑量限制性毒性(DLT)評估及藥代動力學(PK) 數據收集。初步療效評估亦同步進行中。2025年第四季度，本公司亦已啟動劑量擴 增的二期臨床研究。 人體免疫系統是涵蓋多重途徑與機制協同作用的複雜結構。本公司的小分子創新藥 物平台（MultiSel-Opt平台）專注於透過選擇性地鎖定多個蛋白質靶點來調節炎症與 免疫反應，並充分發揮小分子化合物的特性，用單一藥物分子實現多重機制協同作 用。MultiSel-Opt平台使我們能夠探索疾病治療的創新機制，以在創新藥物研發項 目中實現硬核創新，使得所產生的候選化合物在業界中同其他藥物比較不存在可 比擬性。此外，MultiSel-Opt平台的另一特色在於專注於優化藥物在疾病部位的分 佈，例如如何設計最佳藥物化合物以實現適當穿 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 Fujian Haixi Pharmaceuticals Co., Ltd. 福建海西新藥創制股份有限公司 福建海西新藥創制股份有限公司（「本公司」及其附屬公司，統稱「本集團」）董事會 （「董事會」）宣佈將於2026年3月30日（星期一）召開董事會會議，以審議及批准本集 團截至2025年12月31日止年度的年度業績以作刊發之用及處理其他事項，包括建 議派付末期股息（如有）。 承董事會命 福建海西新藥創制股份有限公司 董事長兼執行董事 康心汕博士 中國福建，2026年3月10日 於本公告日期，執行董事為康心汕博士、Feng Yan女士、Chen Guangming博士及陳樞儀博士；非執 行董事為許冬先生及王忻琨先生；及獨立非執行董事為龔為民先生、王珊珊女士及蒲美婷女士。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2637） 董事會會議召開日期 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2637） Fujian Haixi Pharmaceuticals Co., Ltd. 福建海西新藥創制股份有限公司 聯席公司秘書、授權代表及法律程序代理人變更 與 豁免嚴格遵守上市規則第 3.28 條及第 8.17 條 聯席公司秘書、授權代表及法律程序代理人變更 福建海西新藥創制股份有限公司（「本公司」）董事（「董事」）會（「董事會」）宣佈，林慧 怡女士（「林女士」）已辭任(i)本公司聯席公司秘書（「聯席公司秘書」）；(ii)《香港聯合 交易所有限公司（「聯交所」）證券上市規則》（「上市規則」）第3.05條項下所規定的本 公司授權代表（「上市規則項下的授權代表」）；(iii)根據香港法例第622章《公司條例》 第16部項下的本公司授權代表（連同上市規則項下的授權代表稱為「授權代表」）；及 (iv)上市規則第19A.13(2)條所規定代本公司在香 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 福建海西新藥創制股份有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02637 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 78,707,270 | RMB | | 1 RMB | | 78,707,270 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | | 本月底結存 | | | 78,707,270 | RMB | | 1 RMB | | 78,707,270 | 本月底法定/註冊股本總額： RMB 78,707,270 第 1 頁 共 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完 整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內 容而引致的任何損失承擔任何責任。 委任高級管理層 福建海西新藥創制股份有限公司（「本公司」，連同其附屬公司稱為「本集團」）董事會 （「董事會」）欣然宣佈張明強博士（「張博士」）已獲委任為本集團研發與全球事務總 裁，自2026年3月1日起生效。 張博士之履歷詳情載列如下： 張博士，65歲，於製藥及生物科技行業擁有豐富經驗。自1997年至2001年，張博 士曾任英國格拉斯哥Organon研究實驗室（現為Merck Sharp & Dohme的一部分）藥 物化學部負責人。加入跨國製藥公司前，張博士聯合創立了多家生物科技公司。 自2003年至2009年，張博士於英國劍橋Biotica Technology Ltd 擔任研發高級副總 裁，引領合成生物學研發工作。自2009年至2011年，張博士就職於羅氏製藥中國 研發中心，擔任首席技術官兼外部研發副總裁。此後，自2011年至2012年，張博 士（再次）加入Merck Sharp & Dohme，並 ...

Group 1 - The company announced the use of idle funds to subscribe to notes linked to a fund issued by Essence Global Investment Limited and China Rock Fund, with a total scale of approximately HKD 400 million, aimed at enhancing capital returns and ensuring liquidity [1] - Following the announcement, the company's stock price increased by 3.76% on the first trading day (February 9), but experienced volatility in subsequent days [1] - Over the five trading days from February 9 to February 13, the stock price showed fluctuations, with a maximum range of 10.16%, indicating mixed market sentiment [1] Group 2 - According to the Q2 2025 financial report, the company recorded a quarterly revenue of approximately CNY 159 million, a quarter-on-quarter increase of 76.7%, and a net profit of CNY 52 million, with a gross margin of 84% [2] - The generic drug business accounted for 98% of the revenue, with centralized procurement products contributing significantly to the growth [2] - Although the financial report data is robust, its release in October 2025 means it has limited direct impact on the current stock price [2]

Core Viewpoint - HaiXi New Drug (02637) announced its investment strategy to utilize idle funds effectively by subscribing to structured notes and a fund, aiming to enhance capital returns while ensuring liquidity and meeting operational needs [1] Group 1: Investment Details - The company plans to invest HKD 200 million in structured notes issued by Essence Global Investment Limited under its USD 1 billion secured structured note program [1] - Additionally, the company will subscribe up to HKD 200 million in China Rock Fund SPC, collectively referred to as the subscription matters [1] Group 2: Financial Strategy - The investment aligns with the company's core objective of improving capital returns while ensuring the safety and liquidity of funds [1] - The strategy also aims to meet the group's daily operational and dividend payment funding requirements [1]

Core Viewpoint - HaiXi New Drug (02637) announced its investment strategy to utilize idle funds for subscribing to structured notes and a fund, aiming to enhance capital returns while ensuring fund safety and liquidity [1] Group 1: Investment Details - The company plans to invest HKD 200 million in structured notes issued by Essence Global Investment Limited under its USD 1 billion secured structured note program [1] - Additionally, the company will subscribe up to HKD 200 million in China Rock Fund SPC, collectively referred to as the subscription matters [1] Group 2: Financial Strategy - The effective use of temporary idle funds aligns with the company's core objective of improving capital returns while meeting operational and dividend payment needs [1]